Satiogen Pharmaceuticals Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $700K
Latest Deal Amount
  • Investors
  • 4

Satiogen Pharmaceuticals General Information

Description

Developer of metabolic mechanism therapy designed to regulate nutrient intake and postprandial glucose. The company's products include a substitute for metformin in gliptin formulations and an OTC nutraceutical that would reduce body weight and postprandial glucose, enabling doctor's to treat type 2 diabetes and obesity without intervention.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 350 10th Avenue
  • Suite 820
  • San Diego, CA 92101
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Satiogen Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 01-Apr-2008 $700K 00000 000 Completed Startup
To view Satiogen Pharmaceuticals’s complete valuation and funding history, request access »

Satiogen Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 00.00 00 00 00 00 000
To view Satiogen Pharmaceuticals’s complete cap table history, request access »

Satiogen Pharmaceuticals Executive Team (5)

Name Title Board Seat Contact Info
Robert Ayling Chief Executive Officer
Carey Ng Ph.D Chief Operating Officer & Board Member
Bronislava Gedulin Ph.D Co-Founder, Vice President, Research & Development & Chief Technology Officer
You’re viewing 3 of 5 executive team members. Get the full list »

Satiogen Pharmaceuticals Board Members (6)

Name Representing Role Since
Carey Ng Ph.D Satiogen Pharmaceuticals Chief Operating Officer & Board Member 000 0000
Howard Greene Satiogen Pharmaceuticals Chairman 000 0000
Jay Skyler MD Satiogen Pharmaceuticals Scientific Advisor & Board Member 000 0000
Michael Horowitz Satiogen Pharmaceuticals Scientific Advisor & Board Member 000 0000
Steve Bloom Satiogen Pharmaceuticals Scientific Advisor 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Satiogen Pharmaceuticals Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andrew Young Angel (individual) Minority 000 0000 000000 0
Howard Greene Angel (individual) Minority 000 0000 000000 0
Mesa Verde Venture Partners Venture Capital Minority 000 0000 000000 0
Robert Ayling Angel (individual) Minority 000 0000 000000 0
To view Satiogen Pharmaceuticals’s complete investors history, request access »